Quick Answer
IRADIMED CORP reported R&D Expense of $2.98 million for fiscal year 2025.
IRADIMED CORP R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $2.98M | +5.0% |
| 2024 | $2.83M | -0.9% |
| 2023 | $2.86M | +25.5% |
| 2022 | $2.28M | +19.6% |
| 2021 | $1.91M | +0.1% |
| 2020 | $1.90M | +32.8% |
| 2019 | $1.43M | -5.6% |
| 2018 | $1.52M | -11.9% |
| 2017 | $1.72M | +27.8% |
| 2016 | $1.35M | -23.6% |
| 2015 | $1.76M | +65.1% |
| 2014 | $1.07M | +5.8% |
| 2013 | $1.01M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $674.4K | +5.5% | -23.1% |
| June 30, 2025 | $877.4K | +9.5% | +40.5% |
| March 31, 2025 | $624.2K | -24.0% | -2.4% |
| September 30, 2024 | $639.5K | +41.3% | -20.2% |
| June 30, 2024 | $801.1K | -16.7% | -2.4% |
| March 31, 2024 | $821.0K | -72.6% | +81.4% |
| September 30, 2023 | $452.6K | -8.0% | -53.0% |
| June 30, 2023 | $962.0K | +45.2% | -67.9% |
- IRADIMED CORP showed an increase of +5.0% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, IRADIMED CORP’s r&d expense has grown by 194.6% (from $1.01 million to $2.98 million).
- The most recent figure is from IRADIMED CORP’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: